Navegar por autor "Lluch, A."

Mostrando ítems 1-5 de 5

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019- Pineda, B.; Díaz Lagares, Ángel; Perez-Fidalgo, J. A.; Burgues, O.; Gonzalez-Barrallo, I.; [et al.]
BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

2019- Barnadas, A.; Munoz, M.; Margeli, M.; Chacon, J. I.; Cassinello, J.; [et al.]
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists

2019- Sanchez-Rovira, P.; Zamora, P.; Salvador-Bofill, J.; Morales, S.; Martinez-Janez, N.; [et al.]
Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval

2019- Ciruelos, E.; Alba, E.; López López, Rafael; Lluch, A.; Martín, M.; [et al.]
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

2020- Lluch, A.; Barrios, C. H.; Torrecillas, L.; Ruiz-Borrego, M.; Bines, J.; [et al.]